newsfilter
← Latest News
GlobeNewswire·

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

  • Altimmune, Inc. (NASDAQ: ALT) will have its management team participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
  • The conference session is scheduled for Wednesday, December 3, 2025, at 2:30 p.m. ET.
  • The event will be webcast \& accessible via the Events section of Altimmune's website.
  • Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver \& cardiometabolic diseases.
  • The company's lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for treating metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), \& alcohol-associated liver disease (ALD).
  • Investor contact is Lee Roth of Burns McClellan, \& media contact is Savannah Valade of Real Chemistry.